Department of Hepatopancreatobiliary Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
BMC Bioinformatics. 2023 May 11;24(1):192. doi: 10.1186/s12859-023-05323-y.
Synaptogyrin-2 (SYNGR2), as a member of synaptogyrin gene family, is overexpressed in several types of cancer. However, the role of SYNGR2 in pan-cancer is largely unexplored.
From the TCGA and GEO databases, we obtained bulk transcriptomes, and clinical information. We examined the expression patterns, prognostic values, and diagnostic value of SYNGR2 in pan-cancer, and investigated the relationship of SYNGR2 expression with tumor mutation burden (TMB), microsatellite instability (MSI), immune infiltration, and immune checkpoint (ICP) genes. The gene set enrichment analysis (GSEA) software was used to perform pathway analysis. Besides, we built a nomogram of liver hepatocellular carcinoma patients (LIHC) and validated its prediction accuracy.
SYNGR2 was highly expressed in most cancers. The high expression of SYNGR2 significantly reduced the overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) in multiple types of cancer. Also, receiver operating characteristic (ROC) curve analysis demonstrated that SYNGR2 showed high accuracy in distinguishing cancerous tissues from normal ones. Moreover, SYNGR2 expression was correlated with TMB, MSI, immune scores, and immune cell infiltrations. We also analyzed the association of SYNGR2 with immunotherapy response in LIHC. Finally, a nomogram including SYNGR2 and pathologic T, N, M stage was built and exhibited good predictive power for the OS, DSS, and PFI of LIHC patients.
Overall, SYNGR2 is a critical oncogene in various tumors. SYNGR2 participates in the carcinogenic progression, and may contribute to the immune infiltration in tumor microenvironment. Our study suggests that SYNGR2 can serve as a predictor related to prognosis in pan-cancer, especially LIHC.
突触融合蛋白 2（SYNGR2）作为突触融合蛋白基因家族的一员，在多种类型的癌症中过表达。然而，SYNGR2 在泛癌症中的作用在很大程度上尚未被探索。
我们从 TCGA 和 GEO 数据库中获取了大量转录组和临床信息。我们研究了 SYNGR2 在泛癌症中的表达模式、预后价值和诊断价值，并研究了 SYNGR2 表达与肿瘤突变负担（TMB）、微卫星不稳定性（MSI）、免疫浸润和免疫检查点（ICP）基因的关系。基因集富集分析（GSEA）软件用于进行通路分析。此外，我们构建了一个肝癌患者（LIHC）的列线图，并验证了其预测准确性。
SYNGR2 在大多数癌症中高表达。SYNGR2 的高表达显著降低了多种类型癌症的总生存期（OS）、疾病特异性生存期（DSS）、无病间隔（DFI）和无进展间隔（PFI）。此外，接受者操作特征（ROC）曲线分析表明，SYNGR2 在区分癌组织和正常组织方面具有较高的准确性。此外，SYNGR2 表达与 TMB、MSI、免疫评分和免疫细胞浸润有关。我们还分析了 SYNGR2 与 LIHC 免疫治疗反应的关系。最后，构建了一个包含 SYNGR2 和病理 T、N、M 期的列线图，该列线图对 LIHC 患者的 OS、DSS 和 PFI 具有良好的预测能力。
总的来说，SYNGR2 是多种肿瘤中的关键致癌基因。SYNGR2 参与致癌进程，并可能有助于肿瘤微环境中的免疫浸润。我们的研究表明，SYNGR2 可以作为泛癌症中与预后相关的预测因子，特别是 LIHC。
